{
    "clinical_study": {
        "@rank": "90689", 
        "arm_group": [
            {
                "arm_group_label": "1st group : WIN-34B 900mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients assigned to 1st group take WIN-34B 450mg BID for 12weeks"
            }, 
            {
                "arm_group_label": "2nd group : WIN-34B 1800mg", 
                "arm_group_type": "Experimental", 
                "description": "Patients assigned to 2nd group take WIN-34B 900mg BID for 12weeks"
            }, 
            {
                "arm_group_label": "3rd group : Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients assigned to 3rd group take Placebo BID for 12weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel, phase\n      II clinical trial and aimed at osteoarthritis of the knee.\n\n      Patients who signed informed consent voluntarily and eligible for this study are assigned\n      randomly to one of 3 groups after 2 week-Washout period.\n\n        1. st group (experimental) : WIN-34B 450mg BID\n\n        2. nd group (experimental) : WIN-34B 900mg BID\n\n        3. rd group (Comparator) : Placebo BID\n\n      Patients will take WIN-34B or Placebo BID for 12 weeks. Based on baseline, after 4\n      weeks(Visit 3) and 12 weeks(Visit 5), Researchers check patients' physical examination,\n      questionnaire, laboratory experiment.\n\n      After 8 weeks(Visit 4), researchers check adverse effects and current medication status via\n      telephone interview.\n\n      After 12 weeks(Visit 5) patients stop taking drugs and after 16 weeks(Visit 6) researchers\n      check patients' physical examination, questionnaire, adverse effects and current medication\n      status."
        }, 
        "brief_title": "A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis, Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Being between 35 and 80 years of age\n\n          2. Diagnosed with Osteoarthritis of the knee at least 3 months\n\n          3. Diagnosed with Osteoarthritis of the knee, based on ACR criteria\n\n          4. Able to communicate with researchers and write questionnaires\n\n          5. At the screening visit, checking 100mm Pain VAS at least 80mm\n\n          6. At randomization(Visit 2), checking 100mm Pain VAS over 50mm\n\n          7. Agreeing to participate and signing informed consent voluntarily\n\n        Exclusion Criteria:\n\n          1. Previous intra-articular injection on knee within 3 months\n\n          2. Previous knee surgery within 6 months or scheduled procedures\n\n          3. Other diseases that could affect or interfere with the therapeutic outcomes\n\n          4. Experiencing habitual use of psychotropic, narcotic analgesic drugs over 1 week\n\n          5. Diagnosed with gastrointestinal diseases, unable to stop medicines during the study\n\n          6. At the screening visit, identified liver dysfunction\n\n          7. At the screening visit, identified renal dysfunction\n\n          8. Patients who cannot take NSAIDs\n\n          9. Pregnancy and breast-feeding (women of childbearing age need pregnancy test)\n\n         10. Physicological or mental disorders, including drug-takers\n\n         11. Orthopedic diseases that could affect or interfere with the therapeutic outcomes\n\n         12. Inappropriate for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01873053", 
            "org_study_id": "KR-KHNMC-OA02"
        }, 
        "intervention": {
            "arm_group_label": [
                "1st group : WIN-34B 900mg", 
                "2nd group : WIN-34B 1800mg"
            ], 
            "description": "Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks", 
            "intervention_name": "WIN-34B", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Osteoarthritis, Knee", 
            "WIN-34B"
        ], 
        "lastchanged_date": "June 5, 2013", 
        "location": {
            "contact": {
                "phone": "82-2-440-8639"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "134-727"
                }, 
                "name": "Kyung Hee University Oriental Medicine Hospital at Gangdong"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee", 
        "overall_contact": {
            "email": "seohbk@hanmail.net", 
            "last_name": "Byung-Kwan Seo", 
            "phone": "82-2-440-6292"
        }, 
        "overall_official": {
            "affiliation": "Kyung Hee University Gangdong Hospital", 
            "last_name": "Dong-Suk Park", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "KWOMAC(Korean Western Ontario and McMaster Universities Osteoarthritis Index)", 
            "safety_issue": "No", 
            "time_frame": "Changes from baseline at 4, 12, 16weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01873053"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kyunghee University Medical Center", 
            "investigator_full_name": "Park Dong-Suk", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pain VAS 100mm", 
                "safety_issue": "No", 
                "time_frame": "Visit1(screening), Visit2(0week), Visit3(4weeks), Visit4(8weeks), Visit5(12weeks), Visit6(16weeks)"
            }, 
            {
                "measure": "KHAQ(Korean Health Assessment Questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "Visit2(0week), Visit3(4weeks), Visit5(12weeks), Visit6(16weeks)"
            }, 
            {
                "measure": "LFI(Lequesne's Functional Index)", 
                "safety_issue": "No", 
                "time_frame": "Visit2(0week), Visit3(4weeks), Visit5(12weeks), Visit6(16weeks)"
            }, 
            {
                "measure": "Nine Point Scale", 
                "safety_issue": "No", 
                "time_frame": "Visit5(12weeks)"
            }, 
            {
                "measure": "Cold-Heat Questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Visit2(0week), Visit3(4weeks), Visit5(12weeks), Visit6(16weeks)"
            }, 
            {
                "measure": "Dose and Frequency of Rescue drug", 
                "safety_issue": "No", 
                "time_frame": "Visit2(0week), Visit3(4weeks), Visit4(8weeks), Visit5(12weeks), Visit6(16weeks)"
            }, 
            {
                "measure": "Safety(Vital sign, Physical examination, Laboratory experiment, ECG, Adverse event)", 
                "safety_issue": "Yes", 
                "time_frame": "Visit1(screening), Visit2(0week), Visit3(4weeks), Visit4(8weeks), Visit5(12weeks), Visit6(16weeks) - There are some differences in subgroup at every visit"
            }
        ], 
        "source": "Kyunghee University Medical Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Kyung Hee University Gangdong Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hamsoa Pharmaceutical Co., Ltd.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Kyunghee University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}